stockrow
Saturday 7 November 2026
Export CVM’s income statement to Excel — free account
Cel-Sci Corporation
- EPS
- +65.4%
- Free cash flow
- −2.33%
- Total debt
- −39.7%
Quarter to June 2026, against a year earlier
1.45
0.08
+5.84%
Follow CVM
Alert me
Cel-Sci Corporation (CVM) P/E ratio
Cel-Sci Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2020 | 0.0× | — |
| Jun 2020 | 0.0× | — |
| Mar 2020 | 0.0× | — |
| Dec 2019 | 0.0× | — |
| 18 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABVC ABVC BioPharma, Inc. compare | n/m |
| CELU Celularity, Inc. compare | n/m |
| EVAX Evaxion A/S - Sponsored ADR compare | n/m |
| NXTC NextCure, Inc. compare | n/m |
| AARD Aardvark Therapeutics, Inc. compare | n/m |
| BYSI BeyondSpring Inc. compare | n/m |
| IGC IGC Pharma, Inc. compare | n/m |
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| CVM Cel-Sci Corporation | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)